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The initiation of transcription by RNA polymerase II is
controlled by the assembly of the basal transcription
machinery, which integrates inputs from transcription
factors bound to promoters and enhancers. Overall, a
typical gene may depend on the binding of tens of tran-
scription factors to its controlling-sequence elements.
Combinatorial assembly ensures that each gene can ex-
hibit a distinctive and sometimes variable pattern of ex-
pression, despite the fact that the number of transcrip-
tion factors is much lower than the number of genes.
DNA is usually represented as a straight thread over
which transcription factors perch like birds on a tele-
phone line. During the past few years, however, it has
been realized that DNA and transcription factors form
a tightly knit three-dimensional structure, in which the
DNA is bent and twisted and in which the proteins es-
tablish a vast number of contacts to each other (Tjian
and Maniatis 1994). This newer model neatly explains
how each transcription factor can establish contactswith
several others, which are not necessarily bound to con-
tiguous sites on the DNA. Hence, the model accom-
modates a large number of otherwise puzzling biochem-
ical data, but it raises a distinct biophysical problem:
DNA is intrinsically a stiff molecule, with very little in-
clination to bend and twist. In dilute solutions, DNA
can be modeled as if it consisted of freely rotating rigid
rods, 300 bp in length; only beyond the kilobase scale
does DNA appear serpentine (Cantor and Schimmel
1980). How, then, is DNA persuaded to follow tightly
curved paths? Perhaps not surprisingly, specialized pro-
teins are responsible.
SRY and the Genetics of Sex Determination
The most famous of DNA-flexing proteins is SRY, the
factor that determines the male sex in mammals (Good-
fellow and Lovell-Badge 1993, and references therein).
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SRY is coded by an intronless gene on the Y chromo-
some, which redirects the undifferentiated gonad of
mammalian embryos from the default developmental
fate (ovaries and female sexual organs), promoting in-
stead the development of testes and male sexual organs.
In the mouse, the Sry gene is expressed in pre-Sertoli
cells at ∼10.5–12.5 d postcoitus. Sry mRNA expression
resumes in the adult testis, but no Sry protein is formed
in this tissue, because the transcript is circularized, leav-
ing no entry point for ribosomes. Approximately 30%
of XX mice transgenic for the Sry gene become infertile
but otherwise apparently normal males. In humans, as
well, the translocation of the genome segment encom-
passing SRY to other chromosomes causes the switch of
XX individuals to male gonads and habitus. Conversely,
mutations of the SRY gene in XY individuals lead to
female phenotypes with variable penetrance.
SRY protein consists of a DNA-binding domain of the
HMG-box class, flanked by protein sequences with little
similarity to other transcription factors. Surprisingly, the
flanking sequences are not homologous in SRY protein
from closely related species (Tucker and Lundrigan
1993; Whitfield et al. 1993). Moreover, all but one of
the known sex-reversing mutations in human SRY pro-
tein encompass the DNA-binding domain, pointing to
a critical role for this segment and little or no role for
the rest of the protein. In particular, no transactivation
domain has been identified. How such a minimal protein
can control gene expression and cell differentiation can-
not directly be tested, however, because, so far, no target
gene for SRY has been identified with certainty. Detailed
information is nonetheless available on the mode of in-
teraction between the HMG box of SRY and DNA.
The HMG-box domain was first recognized as du-
plicated 80-amino-acid regions present in the abundant
nonhistone chromatin protein HMG1. Similar sequences
are also present in a variety of transcription factors, and
there are currently 1100 examples known (reviewed in
Bianchi 1995). All of these proteins share amarked effect
on DNA structure and an affinity for distorted DNA
structures such as four-way junctions (Bianchi et al.
1989) and bent cisplatin adducts (Pil and Lippard 1992).
In addition, some of these proteins, including SRY, rec-
ognize specific sequences in linear DNA, with high af-
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Figure 1 Structure of the complex between the HMG box of
human SRY and the octanucleotide GCACAAAC. HMG boxes are
composed of three a-helices and an extended amino acid stretch at
their N-terminus. The Ca backbone of the SRY HMG-box (magenta)
is almost exactly superimposable upon that of HMG boxes frommam-
malian HMG1 andDrosophilaHMG-D, which share only∼20% iden-
tity in primary sequence. The DNA (yellow) is significantly distorted:
the minor groove is widened considerably to accommodate the ex-
tended stretch of the HMG box; the planes of the bases are tilted; and
the double helix is unwound and bent. Very similar features are also
present in DNA complexed to TBP, which also binds via the minor
groove but which has a completely different protein fold. The contact
between the HMG box and the DNA occurs over a surprisingly large
area and with a very tight fit; thus, the energetic cost of distorting the
DNA is more than compensated by the chemical energy freed by the
protein-DNA interaction. This model is derived from the atomic co-
ordinates provided by Werner et al. (1995). Figure 2 Model for the action of SRY and other HMG-box
proteins. An HMG-box protein (orange) such as SRY binds to target
DNA sequences, which it bends considerably. The angle in the DNA
depicted here approximates that caused by SRY. The flexure of the
DNA brings proteins (blue and green) bound to each side of the site
into proximity, thus promoting their interaction. The presence of con-
tact surfaces between SRY and one or both neighboring proteins may
stabilize the whole complex and increase its target specificity. The same
model can apply to HMG1. HMG1 binds to DNA regardless of se-
quence, so protein-protein interactions with partners are essential to
direct it to the DNA sites where flexing is to occur.
finity and moderate selectivity. The molecular basis of
these unusual binding specificities is revealed by the
structure of a complex between a DNA octamer and the
DNA-binding domain of SRY (fig. 1;Werner et al. 1995).
The HMG box of SRY has an L-shaped structure formed
by an extended segment and three a-helices, stabilized
by hydrophobic contacts. The concave side of the protein
contacts the minor groove of the DNA, over a surpris-
ingly large surface area. The minor groove is extensively
widened to accommodate the extended segment of the
protein domain, and the double helix is unwound by a
succession of positive roll angles and is bent back by
70–80.
The observations that SRY consists essentially of the
DNA-binding domain and that it bends DNA have led
to the proposal that DNA flexing might be the main
activity of SRY. The local structural deformation that
SRY induces in the double helix might mediate effects
at a distance, via the mechanical displacement of the
DNA segments (and associated factors) at either side of
the point of flexure (fig. 2). In accordance with this idea,
a human SRY mutation that causes a very moderate
reduction of the affinity of protein binding to target
sites—but a marked variation in the angle of flexure of
the DNA—was found to cause sex reversal with full
penetrance, as mutations that completely abolish DNA
binding (Pontiggia et al. 1994). A critical prediction in
the DNA-flexing hypothesis, however, is that SRY should
be a component of a multiprotein complex, whose sta-
bility it promotes. Again, this prediction cannot be
tested, for lack of a known target gene for SRY. Inter-
esting clues are nonetheless offered by the biology of
other HMG-box proteins.
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HMG1 and Its Relatives
HMG1, which gives the name to the whole family, is
a very abundant nuclear protein in all mammalian cells:
11 million HMG1 molecules may be found in a single
nucleus (reviewed by Bustin and Reeves 1996). It has
two close relatives, HMG2 and the recently discovered
HMG4 (Vaccari et al. 1998), which are expressed in
embryos and in a limited number of adult tissues.HMG1
and its relatives are composed of two HMG boxes and
a long acidic tail, separated by short linker sequences.
The tail is longest in HMG1 (30 aspartic and glutamic
acid residues) and shortest in HMG4; no specific func-
tion has been attributed to it so far, and certainly it has
no transactivation potential (Landsman and Bustin
1991). Thus, mammalian HMG1-like proteins consist
almost entirely of their DNA-binding domains. Their
primary sequence is extremely conserved in all verte-
brates and down to echinoderms; distantly related pro-
teins are also present in insects, plants, and fungi.
HMG1 shares very similar domain structures and
DNA-binding features with SRY. It binds avidly to four-
way junctions and other DNA molecules displaying a
widened major groove. Ring-closure assays show, con-
versely, that, when present at high concentrations, it
bends short linear-DNA fragments on binding. Unlike
SRY, however, HMG1 has no sequence specificity and
binds very inefficiently to linear DNA. This lack of spec-
ificity in DNA target sites is offset, in the case of HMG1,
by several specific interactions with such DNA-binding
proteins as Oct and Hox proteins (Zwilling et al. 1995;
Zappavigna et al. 1996), nuclear hormone receptors
(Boonyaratanakornkit et al. 1998), p53 (Jayaraman et
al. 1998), RAG1 (V. Aidinis, T. Bonaldi, M. Beltrame,
S. Santagata, M. E. Bianchi, and E. Spanopoulou, un-
published data) and some components of the basal tran-
scription machinery (Sutrias-Grau et al., in press, and
references therein). Strikingly, all such partners interact
directly with HMG boxes, via their DNA-binding do-
main. In doing so, these proteins increase the protein
surface contacting the DNA, from both the major and
minor groove, to ultimately achieve high-affinity inter-
action with their cognate DNA site, without affecting
sequence specificity. How these diverse protein foldsmay
all interact with HMG boxes is unclear at this time.
Protein-protein interactions also occur in the absence of
DNA but are rather weak and dynamic. They can easily
be verified by copurification of the components, but
yeast two-hybrid screens have proved disappointing for
this purpose. Within the cell nucleus, the large pool of
HMG1 probably interacts with a variety of macromol-
ecules, including nucleosomes (Falciola et al. 1997, and
references therein). In vitro, HMG1 forms stable com-
plexes with reconstituted nucleosomes. It is not a com-
ponent of condensed metaphase chromosomes, and it
readily diffuses away from the chromatin of detergent-
permeabilized interphase cells. The most telling obser-
vation is that, abundant as it is, HMG1 is limitingwithin
cells: transient overexpression of HMG1 enhances the
transcriptional activity of Hox protein and steroid hor-
mone receptors, as well as the yield of V(D)J recombi-
nation products, in transfection assays (Zappavigna et
al. 1996; Boonyaratanakornkit et al. 1998) (V. Aidinis,
T. Bonaldi, M. Beltrame, S. Santagata, M. E. Bianchi,
and E. Spanopoulou, unpublished data). The emerging
picture, thus, is that HMG1 serves as an all-purpose
DNA-bending, -wrapping, and -looping factor that can
be recruited for transcription, DNA repair, and recom-
bination. It is therefore not surprising that no human
mutation in HMG1 has been reported so far. Genetic
information is expected from the targeted deletion of the
mouse Hmg1 gene, currently underway in our lab.
Building up Targeting Specificity
This brief review of HMG1 molecular and cellular
biology suggests that a ubiquitous and abundant protein
with no sequence specificity can be directed where DNA
flexing is required by interactions with its partners. Such
protein-protein interactions may well help localize se-
quence-specific DNA-flexing proteins, too. More than
400,000 sites with sufficient affinity for SRY are ex-
pected in the human haploid genome, a problem that is
exacerbated by the existence of multiple proteins with
DNA-binding domains very similar to SRY, conferring
exactly the same binding specificity. There are 120 SOX
(Sry HMG box) genes in mammals, although some have
been identified only via the PCR-derived sequence cod-
ing for their conserved HMG box (Pevny and Lovell-
Badge 1997). Most Sox proteins are expressed in the
developing nervous system and are involved in neural
determination, but a few are also expressed in other
embryonic and adult tissues.
Target genes for some SOX proteins have been iden-
tified: Sox-2 binds the Fgf-4 enhancer (Ambrosetti et al.
1997), whereas Sox-9 binds the enhancer of the collagen
gene Col2a1 (Bell et al. 1997). In vitro, the binding spec-
ificity of Sox-2, SRY, and Sox-9 HMG boxes is indis-
tinguishable, as is the degree of bending that they impose
on DNA (M. E. Bianchi, unpublished data). In vivo,
some target specificity may derive from the pattern of
expression of different SOXs, but a lot certainly derives
from interaction with partners. Sox-2 interacts withOct-
3 (Ambrosetti et al. 1997), Sox-10 with Oct-6 (Kuhl-
brodt et al. 1998b), and Sox-11 with Brn-1 (Kuhlbrodt
et al. 1998a). Where tested, interactions were found to
occur between the HMG box and the POU domain in
the partner, suggesting that a SOX-POU code may exist.
Moreover, in all cases, SOX domains and POU domains
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bind to contiguous sites on the DNA, and the partners
interact synergistically in driving the expression of re-
porter genes. As predicted bymodels that implicateDNA
flexing, the spacing of the binding sites of the protein
partners is essential for proper regulation of target genes
(Ambrosetti et al. 1997; Kuhlbrodt et al. 1998a), and
mutations that alter the DNA-bending ability of SOXs
affect the transcription of target genes (P. Scaffidi and
M. E. Bianchi, unpublished data).
On the basis of the features of other HMG-box pro-
teins, SRY is strongly predicted to have a partner, which
is expected to interact with it via its HMG box. Two-
hybrid screens for SRY interactors have been performed
in several laboratories, and, indeed, a single human 34-
kD protein called “SIP-1” (SRY interacting protein) has
been identified (Poulat et al. 1997). This protein is ubiq-
uitous, nuclear, and interacts, via its two PDZ domains,
with the most C-terminal seven amino acids in human
SRY. No such interaction is seen with rodent Sry; because
the non-HMG box segments of the Sry protein diverge
from the human SRY, it is possible that SIP-1 interacts
with SRY in humans only and that the mouse Sry partner
might be an entirely different protein. A candidate-pro-
tein approach might work best to uncover more SRY
partners. Good candidates include the transcription fac-
tors of the POU family, whose interactions with Sox
proteins are well documented but are not evident by the
two-hybrid method. Several nuclear hormone receptors
and homeodomain proteins have been shown to interact
with HMG1 and, therefore, should be considered as po-
tential SRY partners. At a minimum, it is clear that the
molecular and cellular biology of HMG1 and other
DNA-flexing proteins have provided a powerful inspi-
ration to understand the three-dimensional aspects of
gene regulation.
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